MarketBeat is discussing EyePoint Pharmaceuticals, a company based in the United Kingdom, as a high-risk investment target.
1 report, 1 independent
Updated Aug 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat is discussing EyePoint Pharmaceuticals, a company based in the United Kingdom, as a high-risk investment target.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Related events
- Ally Financial received a Strong Buy rating at $55 from Raymond James, while EyePoint Pharmaceuticals had its target slashed 80% to $4.
- MarketBeat aggregated analyst recommendations and price targets for BioMarin Pharmaceutical and Abeona Therapeutics Inc.
- MarketBeat published consensus ratings and price targets for Sidus Space and HEICO on September 13, 2026.
- MarketBeat has reported on analyst recommendations for MSA Safety and Trinity Industries, comparing their profitability, valuation, and risk profiles.
- Ionis Pharmaceuticals filed institutional investment disclosures and received analyst rating coverage on August 30, 2026.